Grand Pharma
Headquartered in Wuhan, China, Grand Pharmaceutical Group Limited (00512.HK) has been publicly listed on the Hong Kong Stock Exchange since 2008. We are committed to transforming patient outcomes, focusing on pharmaceutical drug development, nuclear medicine for tumor diagnosis and treatment and cerebro-cardiovascular precision intervention technologies. Grand Pharmaceutical’s business spans multiple areas, including nuclear medicine for cancer diagnosis and treatment, precision diagnostics and interventions for cardiovascular and cerebrovascular conditions, respiratory and critical care, ENT (ear, nose, and throat) specialties, emergency cardiovascular care, APIs, mRNA, and amino acids. We have established partnerships with leading pharmaceutical companies, universities, and research institutions from the United States, Australia, Germany, and Belgium, allowing us to advance in cutting-edge medical treatments. With a strong focus on innovation, we currently operate 8 R&D centers worldwide.
Nuclear Medicine for Anti-Tumor Diagnosis and Treatment
We have developed a pipeline of 12 globally innovative products across 5 radioisotopes, addressing 7 types of cancer. Our portfolio includes both diagnostic and therapeutic solutions, offering patients a range of treatments for multiple indications.
Cerebro-Cardiovascular Precision Intervention Diagnosis and Treatment
With a focus on pathway management, structural heart disease, electrophysiology, and heart failure, we have built a comprehensive portfolio of high-tech medical devices, positioning us to become a leading provider of precision cardiovascular and cerebrovascular interventional solutions in China and globally.
We have a solid foundation in respiratory and critical care, ENT, and cardiovascular fields, with market-leading drugs and a robust pipeline of innovative products in development.
Respiratory and Critical Care
We leverage internal R&D and global strategic partnerships to build a comprehensive pipeline for chronic airway disease management and critical care, continuously reinforcing our leadership in these areas.
Eye, Nose, and Throat (ENT)
Our therapeutic portfolio covers multiple specialties, including ophthalmology, ENT, and oral care, offering a wide range of solutions such as prescription drugs, OTC drugs, traditional Chinese medicines, health products, , medical devices, and consumer goods. With extensive distribution across hospital and retail channels, we are building an integrated ecosystem focused on "prevention, treatment, and wellness" for comprehensive specialty care.
Cerebro-Cardiovascular
We have developed a robust portfolio of nearly 30 products for cardiovascular emergency interventions and chronic disease management. 14 of these products are listed on China’s National Emergency Rescue Drug List, and 16 are included on the Shortage Drug List. Our comprehensive pipeline addresses three critical emergency scenarios: in-hospital care, pre-hospital care, and community response, positioning us as an industry leader in life-saving solutions.
Active Pharmaceutical Ingredients (APIs)
We focus on cardiovascular, anti-infective, and analgesic treatments, supporting pharmaceutical formulation and production to ensure high standards and consistent quality from the source. This approach allows us to seamlessly integrate strengths across the entire value chain.
mRNA Technology
We focus on developing mRNA-based therapies for oncology and anti-infective applications, supported by our mRNA production and lipid nanoparticle (LNP) delivery platforms. Our pipeline includes the therapeutic cancer vaccine ARC01 (A002), targeting HPV-16-positive solid tumors. In January 2024, ARC01 received approval in China to initiate Phase I clinical trials, making it the country's first mRNA therapeutic cancer vaccine approved for HPV-positive tumor trials.
We are a leading global supplier of high quality amino acids, committed to technological innovation and stringent quality assurance. Our products are backed by extensive domestic and international certifications, ensuring excellence in every batch. With over 300 patents and a portfolio of 50 amino acid types, we serve customers in more than 140 countries worldwide.